Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
MAIA Biotechnology, Inc. ( (MAIA) ) has shared an update.
On March 2, 2026, MAIA Biotechnology, Inc. entered into an underwriting agreement with Konik Capital Partners, LLC for an underwritten public offering of 20,000,000 shares of common stock at a public price of $1.50 per share. The deal, which included a 30-day option for the underwriter to buy up to 3,000,000 additional shares to cover over-allotments, closed on March 4, 2026, generating approximately $30 million in gross proceeds.
The company and its officers and directors agreed to a 60-day lock-up on specified securities, signaling a near-term commitment to capital structure stability following the raise. MAIA plans to use the net proceeds from the offering to fund clinical trials, as well as for working capital and general corporate purposes, supporting ongoing development of its oncology pipeline and potentially strengthening its position in the competitive immuno-oncology market.
The most recent analyst rating on (MAIA) stock is a Buy with a $14.00 price target. To see the full list of analyst forecasts on MAIA Biotechnology, Inc. stock, see the MAIA Stock Forecast page.
Spark’s Take on MAIA Stock
According to Spark, TipRanks’ AI Analyst, MAIA is a Neutral.
MAIA Biotechnology presents a mixed outlook. The company’s financial performance is weak due to its development-stage status and lack of revenue, contributing to a low financial performance score. However, recent positive trial results and technical indicators showing short-term upward momentum provide a more optimistic view. Valuation remains challenging due to negative earnings, but the potential for significant clinical advancements offers upside potential.
To see Spark’s full report on MAIA stock, click here.
More about MAIA Biotechnology, Inc.
MAIA Biotechnology, Inc. is a clinical-stage biopharmaceutical company focused on targeted therapy and immuno-oncology, developing potential first-in-class drugs with novel mechanisms of action to treat cancer. Its lead program, ateganosine (THIO), is a telomere-targeting agent in clinical development for non-small cell lung cancer patients with telomerase-positive tumors.
Average Trading Volume: 1,097,384
Technical Sentiment Signal: Sell
Current Market Cap: $58.38M
Learn more about MAIA stock on TipRanks’ Stock Analysis page.